Finally, transferrin saturation > 20% after 6 weeks after FCM dose was attained by 63% of all patients, 69% of patients in both IDA and iron deficiency without anemia groups, 63% in the diseases of the digestive system group, 68% in the diseases of the genitourinary system group, 67% in the neoplasms group, and 47% in the diseases of the circulatory system group. This evidence concerns the gene TF and neoplasm.